Alumis (ALMS) Chief Medical Officer awarded 221,450 stock options

Rhea-AI Filing Summary

Alumis Inc. reported that Chief Medical Officer Jorn Drappa received a new stock option grant. The option covers 221,450 shares of common stock at an exercise price of $26.31 per share, awarded on January 26, 2026.

According to the vesting terms, 25% of the shares vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Drappa’s continuous service under the company’s 2024 Equity Incentive Plan and subject to potential acceleration provisions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Drappa Jorn

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	221,450	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 221,450 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drappa Jorn

(Last) (First) (Middle)

C/O ALUMIS INC.

280 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALUMIS INC. [ ALMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.31	01/26/2026		A		221,450		(1)	01/25/2036	Common Stock	221,450	$0	221,450	D

Explanation of Responses:

1. 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

	/s/ Sanam Pangali, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alumis (ALMS) report for Jorn Drappa?

Alumis reported a stock option grant to Chief Medical Officer Jorn Drappa. The award covers 221,450 shares of common stock, giving him the right to buy shares at a fixed exercise price under the company’s 2024 Equity Incentive Plan.

How many Alumis (ALMS) shares are covered by Jorn Drappa’s new option?

The new stock option granted to Jorn Drappa covers 221,450 shares of Alumis common stock. This derivative award provides potential future ownership, depending on vesting and exercise, rather than immediate stock ownership on the grant date.

What is the exercise price of Jorn Drappa’s Alumis (ALMS) stock option?

The exercise price of Jorn Drappa’s stock option is $26.31 per share. This is the price he must pay per share if he chooses to exercise the option once the underlying option shares have vested.

When does Jorn Drappa’s Alumis (ALMS) option start vesting?

Vesting for Jorn Drappa’s option begins on January 26, 2027, when 25% of the underlying shares vest. This initial cliff vesting date marks the first point at which a portion of the option can potentially be exercised.

What is the vesting schedule for Jorn Drappa’s Alumis (ALMS) stock option?

After 25% vests on January 26, 2027, the remaining shares vest in equal monthly installments over the next 36 months. Vesting depends on Drappa’s continuous service and follows terms in the 2024 Equity Incentive Plan.

When does Jorn Drappa’s Alumis (ALMS) stock option expire?

The stock option granted to Jorn Drappa expires on January 25, 2036. After that date, any unexercised portion of the option terminates, and he can no longer purchase shares under this specific award.